Physician

Viral Kantilal Rabara, MD

According to 2025 Medicare claims, Viral Rabara, MD (NPI: 1669788170) practices medical oncology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from York, SC. This provider's primary affiliated billing organization is CAROLINA BLOOD AND CANCER CARE ASSOCIATES, P.A. (NPI: 1013002013; TIN: 35-2221941) and primary practice location at 29732-3858.

Rabara's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 420 traditional Medicare patients, billed 98,410 HCPCS/CPT codes, and received $1,998,660 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,237 prescription claims across 217 beneficiaries totaling $3,918,234 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2019 DME data shows 26 claims. Open Payments data shows 201 records totaling $60,346. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $5,916 to $1,998,660. Similarly, Part D prescription costs have moved sharply higher in recent years, from $70,903 to $3,918,234. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	55	60	$5,916
2016	N/R	N/R	N/R
2017	16	46	$2,414
2018	596	68,031	$558,071
2019	530	92,027	$845,606
2020	399	102,075	$1,387,316
2021	388	110,663	$1,258,595
2022	410	138,131	$2,001,190
2023	501	112,039	$1,795,545
2024	420	98,410	$1,998,660

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	100	289	$70,903
2016	115	460	$335,884
2017	81	249	$228,938
2018	172	701	$965,948
2019	148	792	$1,326,535
2020	153	931	$1,376,946
2021	160	1,017	$2,274,830
2022	199	992	$1,991,406
2023	207	1,105	$3,130,688
2024	217	1,237	$3,918,234

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$18,304
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	26	$3,736
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	86	119	$81
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	256	664	$60
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	129	525	$42
36415	Insertion of needle into vein for collection of blood sample	288	859	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	318	1,038	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	37	1,110	$504,501
Pomalyst	Pomalidomide	12	336	$319,649
Brukinsa	Zanubrutinib	34	1,020	$317,661
Tasigna	Nilotinib Hcl	13	384	$261,130
Revlimid	Lenalidomide	13	364	$235,142

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	191	$12,123	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	10	$48,223	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Viral Kantilal Rabara, MD?

Tedicare shows public-source Medicare data for Viral Kantilal Rabara, MD (NPI 1669788170), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Viral Kantilal Rabara, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Viral Kantilal Rabara, MD?

Viral Kantilal Rabara, MD is linked to CAROLINA BLOOD AND CANCER CARE ASSOCIATES, P.A. (billing NPI 1013002013) in the available physician profile data.

Does Viral Kantilal Rabara, MD have Open Payments data?

Viral Kantilal Rabara, MD has 201 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.